Lorenzo Gerratana

Physician scientist @CroAviano | Assoc Professor @Uniud | Chief Data Officer @ PMAC #PrecisionMedicine, #LiquidBiopsy, #Retrocomputing, Mac Geek, Ramen Addicted

[Centro di Riferimento Oncologico IRCCS @CroAviano]

🔬Tumore al seno: dal Registro Tumori FVG dieci anni di dati sui progressi nella #diagnosi e nella #cura. Pubblicato su The Oncologist uno studio del CRO di Aviano su oltre 10.400 donne. Scopri di più👉https://t.co/ddy565iHQh

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Letter in @Nature_NPJ👉SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in #MetastaticBreastCancer.

🔓https://t.co/thAiacu74F

@BianchiniGP @breastoncdoc @JavierCortesMD @curijoey @Shaheenah1 @LGerratana @antgiorda @MIgnatiadis @KalinskyKevin @elmayermd @BCJoyceO @drsarahsam @PedramRazaviMD @PTarantinoMD @GustavoWerutsky #MBC

[OncoDaily @oncodaily]

IAPM - Global Oncology Experts Confront Precision Care Challenges at ASCO 2026

https://t.co/INRhPqBx53

@united4cancer @ASCO @MassimoCristof9 @LGerratana @SanaAlSukhun @antoniomarraMD

[Mirrors of Medicine @mirrorsmed]

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus (Review)

https://t.co/B4MiL5AkVq

PIK3CA 🧬mutations are key actionable biomarkers in advanced HR+/HER2− #BreastCancer , guiding use of PI3K inhibitors like alpelisib and inavolisib. Next-generation sequencing is preferred to detect canonical and non-canonical variants. Tumor tissue is the primary testing source, with liquid biopsy🩸 as an alternative.

Activating mutations in tissue or plasma identify eligible patients. Consensus recommendations standardize testing, reporting, and clinical integration to improve care and align with current evidence.

@curijoey
@BianchiniGP
@UmbertoMalapel1
@LGerratana
@NicolaFuscoMD
@dariodebiase
@CarmineDeA1
@puglisi_fabio
@grazia_arpino
@delmastro_lucia
@ALEDIGNUS12
@OncoAlert 🚨

[Over @OverEventi]

Pratica clinica, confronto, visione. 🩺 È in corso oggi Evolving Therapies, una giornata di confronto concreto su una delle sfide più complesse in oncologia mammaria.

Il #TNBC è al centro di una discussione viva e dinamica, orientata anche al futuro ma con un impatto immediato sulla gestione quotidiana dei pazienti.

Il dialogo tra esperti si conferma fondamentale: è qui che la complessità trova risposte concrete.

Grande partecipazione e coinvolgimento anche nei momenti interattivi – escape room clinica e decision game – pensati per tradurre la conoscenza in pratica clinica reale, dove ogni esperienza contribuisce a ridefinire il percorso di cura.

Un ringraziamento speciale ai Responsabili Scientifici, Carmine De Angelis e Matteo Lambertini, per aver guidato l’ideazione di questa giornata, e a tutta la Faculty per aver arricchito questa giornata di formazione.

Grazie anche a Gilead per il supporto non condizionante.

@CarmineDeA1 @matteolambe @BlondeauxEva, @DottBotticelliA, @Roberta27585687, @BenedettaConte5, @CarmenCriscit, @vitti10, @LGerratana, @ArmandOrlandi, @marti_pagliuca, @MariaVitaSano1, @angela_toss

[Luca Arecco, MD @Lucarecco]

Out in @eClinicalMed a network M-A evaluating treatment strategies after PD on CDK4/6i in HR+/HER2− mBC
Results support biomarker-driven algorithm and are relevant since head-to-head trials are unlikely to be conducted!

Congrats @RobertoBuonaiu3 @CarmineDeA1 ��
@OncoAlert

[Carmine De Angelis @CarmineDeA1]

🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔
💻We conducted a systematic review & NMA to guide evidence-based decisions.
📰Read more: https://t.co/3QUFaERmUw
@OncoAlert
@oncodaily
@eClinicalMed

[Lorenzo Gerratana @LGerratana]

Just wrapped up the 2025 GIM annual meeting

Proud of our fellows and postdocs who blew us away with exciting new trial ideas: the #NextGeneration of #oncology #research is already here.

#GIM #liquidbiopsy #PrecisionMedicine

[Over @OverEventi]

Riunione annuale GIM – Gruppo Italiano Mammella 📍 Domani 26 e 27 settembre a Bergamo.

Il #GIM è uno dei principali consorzi indipendenti per la ricerca sul carcinoma mammario, con oltre 150 centri e 500 sperimentatori coinvolti.
L’appuntamento annuale è un momento chiave per condividere risultati, aggiornarsi sui trial in corso e proporre nuovi studi, favorendo confronto e networking tra i maggiori esperti e giovani ricercatori del settore.
Responsabili Scientifici: Alberto Zambelli, Armando Santoro.

Comitato organizzatore: @arpino_grazia, @delmastro_lucia, Michelino De Laurentiis @MicheleDelauren, Sabino De Placido, Alessandra Fabi, @puglisi_fabio.

👉 Guarda il programma: https://t.co/jUNJ8F9uDA

#GIM #BreastCancer #Oncologia #ClinicalResearch

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New Study 👉Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive #MetastaticBreastCancer: A biomarker analysis from the PACE phase II study. #ctDNA #MNC #BreastCancer
📎https://t.co/gPQaVax5Pk
@LGerratana @ReduzziCarol @RMJesel @AngieDemichele @jane_meisel @YAbdouMD @KUMedCenter @NaomiKoMD @DrHBurstein @MKDeMeo @stolaney1 @elmayermd

[Lorenzo Gerratana @LGerratana]

Treatment impact adjusted for clinical + ESR1, RB1, PIK3CA ctDNA:

Stage IV aggressive
▪️ F+P HR 0.39
▪️ F+P+A HR 0.19

Stage IV indolent
▪️ F+P HR 1.17
▪️ F+P+A HR 0.99

Interaction p=0.0148 & 0.0033

[Lorenzo Gerratana @LGerratana]

Biomarker analysis of the PACE trial in HR+/HER2– #metastatic #breastcancer after CDK4/6i:

‼️Baseline #CTC enumeration (≥5 CTCs) identifies patients with extended PFS from F+palbociclib (F+P) or F+P+avelumab vs fulvestrant (F) alone.

👉🧵 A thread
https://t.co/NRc31QGZWf

[Lorenzo Gerratana @LGerratana]

🧬 Patients with Stage IV aggressive disease had a higher prevalence of ESR1 and RB1 mutations, while no difference were observed for PIK3CA

🔹 ESR1 → 62.6% vs 41.3% (p=0.0008)
🔹 RB1 → 18.2% vs 4.8% (p=0.0031)

[Eleonora Nicolò @eleonora_nicolo]

Mark your calendar for the International Inflammatory Breast Cancer Symposium!

🗓️ October 23, 2025
📍 Milan (Italy)
🌐 Join��in person or online

Don’t miss this opportunity to connect with global IBC experts, share ideas, and advance research to improve patient outcomes.

[OncoAlert @OncoAlert]

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

https://t.co/tHh9xhaiUl

In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus lapatinib (with endocrine therapy for hormone receptor-positive patients) was compared to trastuzumab with physician-selected chemotherapy in 59 patients who had received at least two prior anti-HER2 regimens. Although the chemotherapy arm showed slightly better clinical benefit rate (26.7% vs. 20.7%), progression-free survival (6.1 vs. 3.6 months), and overall response rate, none of these differences reached statistical significance, and overall survival was nearly identical between arms. Adverse events were more frequent and severe in the lapatinib group, yet this arm was associated with better quality of life.

These findings, though exploratory due to early study closure and limited sample size, suggest that trastuzumab plus lapatinib could be a tolerable, chemotherapy-free alternative in select patients prioritizing quality of life.

@CarmineDeA1
@marti_pagliuca
@Roberta27585687
@SCinieri
@alessandrafab11
@delmastro_lucia
@puglisi_fabio
@arpino_grazia

Breast
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @itrisabel

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

[Lorenzo Foffano @lfoffano97]

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬

👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC.

https://t.co/c7w9ir8iZ5

[Aldo Caltavituro @ACaltavituro]

📢 Just out on @CROH our Italian Delphi consensus 🤝🏻on the evolving landscape of HR+/HER2- mBC (EVOLVE).

💊Resistance/sensitivity to CDK4/6i+ET

🧬Biomarkers

🔎Treatment algorithm

📃: https://t.co/LiAwSn8yDn

Proud to be part of this huge national effort.

[Lorenzo Gerratana @LGerratana]

It’s an honor and an incredible opportunity to be part of this project!

Looking forward to diving into #liquidbiopsy and treatment resistance in ER+/HER2- metastatic #breastcancer.

📅 June 11, 2:00pm EDT
Join us! 👇

#ASCO25 #bcsm #GRASPPosters #GRASPatASCO #MBC #ctDNA

[GRASP @GRASPtweets]

#HotTopicAlert — Liquid biopsy in ER+/ZHER2- metastatic breast cancer to evaluate treatment resistance with GRASP scientist @LGerratana. Join us on June 11 at 2:00pm. Register today at https://t.co/4VKokxgE8x
#asco #asco2025 #bcsm #registertoday #GRASPPosters #GRASPatASCO

[GRASP @GRASPtweets]

Join UNC's Assistant Professor of Medicine @YAbdouMD on June 12 as she discusses racial inequities and HER2-Negative breast cancer. This group will fill up fast, so make sure you register today
https://t.co/MHgYtUr9jQ
#asco2025 #bcsm #registertoday #GRASPPosters #GRASPatASCO

[GRASP @GRASPtweets]

Join Mentor @JaniceTNBCmets on Wednesday, June 12 at 2:00 pm as she leads the discussion on Triple-Negative Breast Cancer and Antibody-Drug Conjugates (ACDs). These sessions fill up fast, so register today!
https://t.co/y1p22q00Uy
#asco #asco2025 #bcsm #registertoday